Program
CHF10067
A development code. Also written as “CHF10067 starting dose -- 1000mg (Cohort A)”, “CHF10067 intermediate dose -- 2000mg (Cohort B)” and “CHF10067 high dose -- 3000mg (Cohort C)”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Chiesi Farmaceutici.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chiesi Farmaceutici | 21 open or running | phase 2since Apr 1, 2026 | Aug 17, 2022 | Jun 27, 2028phase 2 · NCT07516951 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2022First study: phase 1 study in Idiopathic Pulmonary FibrosisFirst studyNCT05513950 · 52 enrolled · North Macedonia, Ukraine, United Kingdom
- Apr 1, 2026Phase 2 study in Idiopathic Pulmonary FibrosisPhase 2 reachedNCT07516951 · 240 planned · United States, North Macedonia, South Korea and more
Ahead
- Jun 27, 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07516951
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07516951Idiopathic Pulmonary Fibrosis · United States, North Macedonia, South Korea and more | 2 | Recruiting | Jun 27, 2028 | 240 |
| NCT05513950Idiopathic Pulmonary Fibrosis · North Macedonia, Ukraine, United Kingdom | 1 | Completed | Jun 17, 2024 | 52 |
How it is read
Names in the registry
- “CHF10067”, 2 entries
- “CHF10067 starting dose -- 1000mg (Cohort A)”, 1 entry
- “CHF10067 intermediate dose -- 2000mg (Cohort B)”, 1 entry
- “CHF10067 high dose -- 3000mg (Cohort C)”, 1 entry
Codes read as this program: CHF10067.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.